Telix Pharmaceuticals: Recruits patients for renal cancer trial

Telix Pharmaceuticals Recruits patients for renal cancer trial

• Telix Pharmaceuticals (TLX) recruits more than 50 per cent of patients required for its ZIRCON phase three study for imaging renal cancer
• The trial will treat around 250 renal cancer patients undergoing kidney surgery to determine the sensitivity and specificity of its drug, TLX250-CDx
• The study has exceeded enrolment expectations despite reduced numbers over the last twelve months due to COVID-19
• The company Chief Medical Officer Dr Colin Hayward says it’s pleasing to see the trial accelerating and a resumption to normal clinical operating conditions
• The company says it expects the trial to complete recruitment over the next four to five months, subject to ongoing pandemic conditions